Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls.

Song IH, Borland J, Savina PM, Chen S, Patel P, Wajima T, Peppercorn AF, Piscitelli SC.

Clin Pharmacol Drug Dev. 2013 Oct;2(4):342-348. Epub 2013 Aug 16.

2.

Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans.

Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, Lou Y, Min SS, Goljer I, Culp A, Piscitelli SC, Savina PM.

Antimicrob Agents Chemother. 2013 Aug;57(8):3536-46. doi: 10.1128/AAC.00292-13. Epub 2013 May 13.

3.

In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.

Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW.

Drug Metab Dispos. 2013 Feb;41(2):353-61. doi: 10.1124/dmd.112.048918. Epub 2012 Nov 6.

PMID:
23132334
4.

Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration--part I.

Torrey CE, Wall HG, Campbell JA, Kwanyuen P, Hoivik DJ, Miller RT, Allen JS, Jayo MJ, Selinger K, Savina PM, Santostefano MJ.

Int J Toxicol. 2005 Sep-Oct;24(5):313-25.

PMID:
16257851
5.

Evaluation of the carcinogenic potential of clofibrate in the p53+/- mouse.

Torrey CE, Campbell JA, Hoivik DJ, Miller RT, Allen JS, Mann PC, Selinger K, Rickert D, Savina PM, Santostefano MJ.

Int J Toxicol. 2005 Sep-Oct;24(5):289-99.

PMID:
16257849
6.

Safety and pharmacokinetics of 5-chloro-2',3'-dideoxy-3'-fluorouridine (935U83) following oral administration of escalating single doses in human immunodeficiency virus-infected adults.

Riddler SA, Wang LH, Bartlett JA, Savina PM, Packard MV, McMahon DK, Blum MR, Dunn JA, Elkins MM, Mellors JW.

Antimicrob Agents Chemother. 1996 Dec;40(12):2842-7.

8.

5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.

Daluge SM, Purifoy DJ, Savina PM, St Clair MH, Parry NR, Dev IK, Novak P, Ayers KM, Reardon JE, Roberts GB, et al.

Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603.

9.

Probenecid-impaired biliary excretion of acetaminophen glucuronide and sulfate in the rat.

Savina PM, Brouwer KL.

Drug Metab Dispos. 1992 Jul-Aug;20(4):496-501.

PMID:
1356724
10.

Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.

Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Savina PM, Blum MR, Prescott DM, Bigner DD, Friedman HS.

Radiat Res. 1992 Feb;129(2):218-23.

PMID:
1734453
11.

Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.

Lilley ER, Elion GB, Dewhirst MW, Schold SC Jr, Blum MR, Savina PM, Laskowitz DT, Bigner DD, Friedman HS.

Cancer Res. 1991 Aug 1;51(15):3906-9.

12.

Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.

Friedman HS, Skapek SX, Colvin OM, Elion GB, Blum MR, Savina PM, Hilton J, Schold SC Jr, Kurtzberg J, Bigner DD.

Cancer Res. 1988 Oct 1;48(19):5397-402.

13.

Optimal perfusion rate determined for in situ intestinal absorption studies in rats.

Savina PM, Staubus AE, Gaginella TS, Smith DF.

J Pharm Sci. 1981 Mar;70(3):239-43.

PMID:
7264883

Supplemental Content

Loading ...
Support Center